• Based on product type, the small molecules API category stays dominant in the specialty API market, during the forecast period.
  • The growing acceptance of small molecules (non-biologics) due to myriad generic drugs in development and patent expiry has resulted in low-cost healthcare expenses which are projected to fuel the specialty API market.